Clinical Trial Search

Primary: Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus — 15; 18; 39; 13 Participants

Primary: Summary of Solicited Local Adverse Events (AEs) — 8; 11; 12; 9 Participants

Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants

Primary: Number of Participants Experiencing Clinical Safety Laboratory Adverse Events — 0; 2; 0; 0 participants

Primary: Systemic and Local Reactogenicity Rates for Ungraded Symptoms — 0; 1; 0; 2 Participants

Primary: Double-blind: Part 1: Percentage of Participants With HDV Ribonucleic Acid (RNA) >=2 log10 IU/mL Decline From Baseline or HDV RNA Target Not Detected (TND) in…

Primary: Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome — 6 Participants

Primary: Number of Participants With All-Cause Mortality — 9; 27; 8 Participants

Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days

Primary: Number of Participants With Seroconversion of HTNV and PUUV Using PsVNA50 — 1; 1; 1; 2 Participants

Primary: Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 — 75.5; 69.2 percentage of participants — p=.544

Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants

Primary: 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) — 11; 13; 25; 34 participants

Primary: Change From Baseline in Copies of HIV DNA Per CD4+ T Cell at Week 24 — 113; 98 HIV DNA copies per CD4+ T cell — p=0.0797

Primary: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness — 3; 9; 4; 6 Participants